Envestnet Asset Management Inc. lessened its stake in Qiagen NV (NASDAQ:QGEN) by 23.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 17,140 shares of the company’s stock after selling 5,294 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Qiagen were worth $530,000 at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in the business. Amalgamated Bank grew its position in Qiagen by 6.1% in the fourth quarter. Amalgamated Bank now owns 43,980 shares of the company’s stock worth $1,360,000 after acquiring an additional 2,523 shares in the last quarter. Bronfman E.L. Rothschild L.P. grew its position in Qiagen by 50.8% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 11,451 shares of the company’s stock worth $354,000 after acquiring an additional 3,860 shares in the last quarter. American International Group Inc. bought a new stake in Qiagen in the fourth quarter worth approximately $154,000. Two Sigma Investments LP grew its position in Qiagen by 0.9% in the fourth quarter. Two Sigma Investments LP now owns 594,920 shares of the company’s stock worth $18,401,000 after acquiring an additional 5,107 shares in the last quarter. Finally, Allianz Asset Management GmbH grew its position in Qiagen by 4.1% in the fourth quarter. Allianz Asset Management GmbH now owns 182,882 shares of the company’s stock worth $5,657,000 after acquiring an additional 7,186 shares in the last quarter. Hedge funds and other institutional investors own 62.23% of the company’s stock.
NASDAQ QGEN opened at $32.82 on Monday. The company has a current ratio of 5.07, a quick ratio of 4.59 and a debt-to-equity ratio of 0.69. Qiagen NV has a 1 year low of $27.83 and a 1 year high of $36.34.
Qiagen announced that its board has initiated a stock buyback program on Wednesday, January 31st that permits the company to buyback $200.00 million in shares. This buyback authorization permits the company to repurchase shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.
Several analysts have commented on the stock. Morgan Stanley decreased their target price on shares of Qiagen from $39.00 to $37.00 and set an “overweight” rating for the company in a research report on Wednesday, April 11th. DZ Bank reissued a “neutral” rating on shares of Qiagen in a research report on Thursday, April 5th. Zacks Investment Research downgraded shares of Qiagen from a “hold” rating to a “sell” rating in a research report on Monday, April 9th. Deutsche Bank reissued a “buy” rating on shares of Qiagen in a research report on Monday, January 22nd. Finally, Commerzbank reissued a “buy” rating on shares of Qiagen in a research report on Thursday, February 1st. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $35.11.
TRADEMARK VIOLATION NOTICE: “Envestnet Asset Management Inc. Reduces Holdings in Qiagen NV (QGEN)” was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.chaffeybreeze.com/2018/04/16/envestnet-asset-management-inc-reduces-holdings-in-qiagen-nv-qgen.html.
Qiagen Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.